John Young currently serves as Group President and Senior Advisor to the Pfizer CEO prior to his retirement from Pfizer in mid-2022. A scientist by training, John has almost 35 years of experience with Pfizer and has held several leadership positions across the organization. Most recently, John was Group President and Chief Business Officer at Pfizer, and a member of the Company’s Executive Leadership Team. As Chief Business Officer, John led a division that integrated all Strategy, Consulting, Business Development, Business Assessment, Portfolio & Decision Analysis, and the Patient & Health Impact reimbursement and access teams. He also played an integral role in the collaborations that led to the successful development and delivery of the Pfizer-BioNTech COVID-19 vaccine. Prior to this role, John was the Group President of Pfizer Innovative Health, which included six business units: Internal Medicine, Inflammation & Immunology, Oncology, Rare Disease, Vaccines and Consumer Healthcare. Each business unit focused on developing innovative breakthrough medicines or vaccines, and on increasing access for patients impacted by diseases with significant unmet need.
John will serve as a member of the Board of Directors of Haleon, the Consumer Healthcare Joint Venture between GlaxoSmithKline and Pfizer when it is separated later this year. He also serves on the Board of Johnson Controls International (JCI).
John holds a BSc in Biological Science from Glasgow University and an MBA from Strathclyde Graduate Business School.